TYME News and Press, Tyme Technologies Inc. From 07/21/20

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will participate at the Canaccord 40 th Annual Growth Conference on Thursday, August 13, 2020. The Company will present its ...

In 1Q21 preliminary results , Tyme Technologies (NASDAQ: TYME ) reports operating cash burn rate of $6.7M, up from $5.9M of the prior quarter due to costs incurred on ongoing TYME-88-Panc phase II trial to evaluate SM-88 as a potential treatment for patients with third-line pancreatic cance...

New Preclinical Data Supporting SM-88 Mechanism of Action Presented at AACR 2020 TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer. PanCAN enrolling patients in its Precision Promise SM adaptive randomized Ph...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that TYME will hold its 2020 Annual Meeting of Stockholders in a virtual-only format, as a result of public health concerns relating to the cor...

TYME-18 leverages unique metabolism of cancer to create an intra-tumoral treatment for inoperable cancers Preclinical animal studies demonstrated TYME-18’s potential to dramatically shrink and/or resolve tumors TYME-18 treatment resulted in a 91.6% (11/12) complete resolutio...

- Preclinical data demonstrated statistically significant tumor reduction in SM-88 treated arms versus controls - Builds on confirmed tumor responses achieved in human clinical studies across 15 different cancer types - Multiple monotherapy effects of SM-88 were shown, including increa...

Lead pipeline investigational compound, SM-88, represents a new approach designed to selectively disrupt cancers metabolic process leading to cancer cell death SM-88 has demonstrated clinical responses in 15 different cancer types across four separate studies TYME-88-Panc pivotal t...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2020 at BIO Digital from June 8-12. For 2020, the BIO International Convention has transiti...

Tyme Technologies, Inc. (TYME) Q4 2020 Earnings Conference Call May 20, 2020 05:00 PM ET Company Participants Brian Gill - Corporate Communications and IR Steve Hoffman - CEO Michele Korfin - COO Jonathan Eckard - CBO Giuseppe Del Priore - CMO Ben Taylor - President and CFO...

Tyme Technologies (NASDAQ: TYME ): FY Non-GAAP EPS of -$0.17 beats by $0.04 ; GAAP EPS of -$0.19. More news on: Tyme Technologies, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...